Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2024*

POTENTIAL APPROVALS US/EU

OPSUMIT (macitentan)
EU Pediatric Pulmonary Arterial Hypertension (TOMORROW)

✓ US **OPSYNVI (macitentan/tadalafil STCT)**
✓ EU Pulmonary Arterial Hypertension

✓ US **EDURANT (rilpivirine)**
✓ EU HIV pediatric 2-12 year old

✓ US^ **BALVERSA (erdafitinib)**
EU Urothelial Cancer (THOR)

US **DARZALEX (daratumumab)**
Frontline multiple myeloma transplant eligible (PERSEUS)

✓ US **CARVYKTI (ciltacabtagene autoleucel)**
✓ EU Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4)

✓ US **RYBREVANT (amivantamab)**
✓ EU Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

US **RYBREVANT / lazertinib**
EU Non Small Cell Lung Cancer 2L (MARIPOSA-2)

US **RYBREVANT / lazertinib**
EU Non Small Cell Lung Cancer (MARIPOSA)

PLANNED SUBMISSIONS US/EU

US **OPSUMIT (macitentan)**
Pediatric Pulmonary Arterial Hypertension (TOMORROW)

UPTRAVI (selexipag)
✓ EU Pediatric Pulmonary Arterial Hypertension (SALTO)

REKAMBYS
✓ EU HIV Adolescents

US **nipocalimab**
EU Generalized Myasthenia Gravis

US **SPRAVATO (esketamine) monotherapy**
Treatment Resistant Depression (TRD4005)

✓ US **RYBREVANT (amivantamab)**
✓ EU Subcutaneous (PALOMA-3)

✓ US **DARZALEX (daratumumab)**
✓ EU Frontline multiple myeloma transplant eligible (PERSEUS)

US **SIMPONI (golimumab)**
EU Pediatric Ulcerative Colitis

STELARA (ustekinumab)
✓ EU Pediatric Crohn's Disease

US **TREMFYA (guselkumab)**
Pediatric Psoriasis

✓ US **TREMFYA (guselkumab)**
✓ EU Crohn's Disease (GALAXI)

US **TREMFYA (guselkumab)**
Pediatric Juvenile Psoriatic Arthritis

✓ US **TREMFYA (guselkumab)**
✓ EU Ulcerative Colitis Monotherapy (QUASAR)

US **TREMFYA (guselkumab)**
Ulcerative Colitis Subcutaneous Induction (ASTRO)

✓ US **TREMFYA (guselkumab)**
✓ EU Crohn's Disease Subcutaneous Induction (GRAVITI)

POTENTIAL CLINICAL DATA

Phase III

✓ **TREMFYA (guselkumab)**
Crohn's Disease (GALAXI)

✓ **TREMFYA (guselkumab)**
Ulcerative Colitis Monotherapy (QUASAR)

✓ **RYBREVANT (amivantamab)**
Subcutaneous (PALOMA-3)

ERLEADA (apalutamide)
High Risk Prostate Cancer (PROTEUS)

✓ **seltorexant**
Adjunctive treatment for major depressive disorder with insomnia symptoms

✓ **nipocalimab**
Generalized Myasthenia Gravis

TREMFYA (guselkumab)
Crohn's Disease Subcutaneous Induction (GRAVITI)

aticaprant
Adjunctive Major Depressive Disorder (VENTURA 1)

✓ **SPRAVATO (esketamine) monotherapy**
Treatment Resistant Depression (TRD4005)

DARZALEX (daratumumab)
Amyloidosis (ANDROMEDA)

Phase II

JNJ-4804 Co-antibody Therapeutic
Psoriatic Arthritis (AFFINITY)

✓ **nipocalimab**
Sjogren's Disease (DAHLIAS)

TAR-200 (RIS/gemcitabine plus cetrelimab)
Non Muscle Invasive Bladder Cancer (SunRISe-1)

J&J

*This information is as of July 17, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. ^ BALVERSA US Full Approval

✓ = Achieved